A phase II trial of FLX-787 in Charcot-Marie-Tooth
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs FLX 787 (Primary)
- Indications Charcot-Marie-Tooth disease
- Focus Therapeutic Use
- Acronyms COMMIT
- 31 Jul 2017 According to a Flex Pharma media release, company is on track to initiate the trial this quarter and data readouts expected in 2018.
- 25 Jul 2017 According to a Flex Pharma media release, the trial is expected to initiate in third quarter 2017.
- 03 May 2017 According to a Flex Pharma media release, the company is planning to submit a protocol to the FDA to start a clinical trial of FLX-787 to treat patients with CMT neuropathy and expects to initiate the study in summer 2017.